^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

MB-CAR-T19-22

i
Other names: MB-CAR-T19-22
Associations
Company:
Miltenyi Biotec
Drug class:
CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
Associations
over1year
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL (clinicaltrials.gov)
P1/2, N=50, Active, not recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Mar 2027 | Trial primary completion date: Dec 2022 --> Mar 2022
Enrollment closed • Trial completion date • Trial primary completion date
|
CD22 (CD22 Molecule)
|
CD19 expression • CD22 expression
|
cytarabine • cyclophosphamide • etoposide IV • fludarabine IV • Actemra IV (tocilizumab) • MB-CAR-T19-22